CAREDX INC

CDNA is the ticker symbol for CareDx, Inc., a company focused on diagnostic and genomic testing for transplant patients. The stock trades on the Nasdaq exchange under this symbol. Investors can use the ticker to track the company's market performance, financial news, and regulatory filings. For the latest price, market cap, and other real-time data, refer to the live quote displayed on this page.

The company develops and commercializes diagnostic solutions for transplant recipients, including non-invasive blood tests to monitor organ health and detect rejection. Its offerings also include digital health platforms and laboratory services used by transplant centers. Revenue is generated through testing services, product sales, and collaborations with pharmaceutical and research organizations.

Recent performance for CDNA depends on market conditions, company earnings, and sector trends. For the most current price change, percentage move, and trading volume, check the live data on this page. Historical price charts and performance comparisons are also available through the stock's quote section and financial news sources.

Valuation for CDNA can be assessed using metrics such as price-to-sales, price-to-book, and enterprise value-to-revenue, especially if the company has not consistently reported positive earnings. Comparing these ratios to peers in the diagnostics and genomics sector provides context. Analysts also consider growth prospects, reimbursement trends, and cash flow. For current ratios, see the valuation data on this page.

To buy CDNA, open a brokerage account that offers access to Nasdaq-listed stocks. Search for the ticker CDNA, enter the number of shares and order type, then submit. Fractional shares may be available depending on the broker. Ensure the order is placed during regular trading hours unless your broker supports extended-hours trading.

Key risks include regulatory changes affecting reimbursement for diagnostic tests, intense competition in the transplant diagnostics market, and reliance on a limited number of large laboratory and hospital customers. The company may also face intellectual property disputes, product development setbacks, and the need for ongoing investment in research and sales. Financial performance can be volatile due to these factors and broader market sentiment.